Encouraging results of photodynamic therapy with Visudyne in a clinical patient material of age-related macular degeneration

Acta Ophthalmologica Scandinavica

Volumn 82, Issue 6, 2004, Pages 645-650

  Frennesson, Christina I ^a   Nilsson, Sven Erik G ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Photodynamic therapy; Verteporfin

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENZOPORPHYRIN DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; BACKACHE; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE DURATION; DIZZINESS; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPOTENSION; INTERMETHOD COMPARISON; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPTIC DISK; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; SWEDEN; SYMPTOMATOLOGY; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

AGED; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RECURRENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 11244296210     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2004.00368.x     Document Type: Article

References (10)

1. Blinder KJ, Blumenkranz MS, Bressler NM et al. (2003): Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial. VIP Report 3. Ophthalmology 110: 667-673.
2. Macular Photocoagulation Study Group (1990): Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 108: 816-824.
3. Macular Photocoagulation Study Group (1991a): Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized trials. Arch Ophthalmol 109: 1109-1114.
4. Macular Photocoagulation Study Group (1991b): Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 109: 1220-1231.
5. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (1999): Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of two randomized clinical trials. TAP Report 1. Arch Ophthalmol 117: 1329-1345.
6. Treatment of Age-related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Groups (2003a): Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin. Fluorescein angiographic guidelines for evaluation and treatment. TAP and VIP Report 2. Arch Ophthalmol 121: 1253-1268.
7. Treatment of Age-related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Groups (2003b): Effect of lesion size, visual acuity and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration. TAP and VIP Report 1. Am J Ophthalmol 136: 407-418.
8. Verteporfin in Photodynamic Therapy Study Group (2001a): Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. VIP Report 2. Am J Ophthalmol 131: 541-560.
9. Verteporfin in Photodynaniic Therapy Study Group (2001b): Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: one-year results of a randomized clinical trial. VIP Report 1. Ophthalmology 108: 841-852.
10. Verteporfin Roundtable 2000 and 2001 Participants & Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators & Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators (2002): Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 22: 6-18.